Nafamostat

Nafamostat

SCHEMBL29358879

N=C(N)c1ccc2cc(OC(=O)c3ccc(N=C(N)N)cc3)ccc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 13/20 1.00
F2 P00734 5/20 1.00
HGFAC Q04756 4/20 1.00
ALDH1A1 P00352 2/20 1.00
PLG P00747 2/20 1.00
TMPRSS2 O15393 1/20 1.00
MLNR O43193 1/20 1.00
C1R P00736 1/20 1.00
F10 P00742 1/20 1.00
F12 P00748 1/20 1.00
LMNA P02545 1/20 1.00
ITGB3 P05106 1/20 1.00
HPN P05981 1/20 1.00
KLK1 P06870 1/20 1.00
CHRM2 P08172 1/20 1.00
ITGA2B P08514 1/20 1.00
C1S P09871 1/20 1.00
ADORA3 P0DMS8 1/20 1.00
MAPT P10636 1/20 1.00
CHRM1 P11229 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nafamostat SCHEMBL29360143 1.00 PRSS1 (1.00) PRSS1F2HGFACALDH1A1PLG
Nafamostat SCHEMBL135504 1.00 PRSS1 (1.00) PRSS1F2HGFACALDH1A1PLG
Nafamostat SCHEMBL25197320 0.93 FTO (1.00) PRSS1F2HGFACALDH1A1PLG
Nafamostat SCHEMBL1650158 0.93 FTO (1.00) PRSS1F2HGFACALDH1A1PLG
SCHEMBL31380450 0.87 F12 (0.76) PRSS1F2HGFACALDH1A1PLG
SCHEMBL23898923 0.86 PRSS1 (0.76) PRSS1F2HGFACALDH1A1PLG
SCHEMBL25633204 0.86 PRSS1 (0.76) PRSS1F2HGFACALDH1A1PLG
SCHEMBL7337750 0.83 F12 (0.71) PRSS1F2HGFACALDH1A1PLG
SCHEMBL7338848 0.83 F12 (0.71) PRSS1F2HGFACALDH1A1PLG
SCHEMBL7342376 0.83 F12 (0.71) PRSS1F2HGFACALDH1A1PLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4185286-A1 TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES National University of Singapore (SG) 2023-05-31 EP claimed
WO-2022019828-A1 TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES NATIONAL UNIVERSITY OF SINGAPORE (SG) 2022-01-27 WO claimed
EP-4308103-A1 ANTIVIRAL COMPOSITIONS AND METHODS AI Therapeutics, Inc. (US) 2024-01-24 EP disclosed
EP-4185286-A1 TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES National University of Singapore (SG) 2023-05-31 EP disclosed
WO-2022197667-A1 ANTIVIRAL COMPOSITIONS AND METHODS YOUNG PETER R (US) 2022-09-22 WO disclosed
US-11400062-B2 Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof SIGNATURE THERAPEUTICS, INC. (US) 2022-08-02 US disclosed
WO-2022019828-A1 TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES NATIONAL UNIVERSITY OF SINGAPORE (SG) 2022-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11400062-B2 Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof ACHE, COMT, CES2 PRSS1 96/4885F2 4549/4885HGFAC 970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.